BroadOak Invests in Kemp Proteins
BroadOak invested in Kemp Proteins, a leading CDMO specializing in the production of novel proteins. The investment will be used to expand Kemp Proteins’ bacteria expression and plasmid production services in Frederick, Maryland. The full press release is below. Kemp Proteins Secures $5M Growth Financing from BroadOak Capital Partners Funding for expansion of facilities to […]
BRT Sells to Medix Biochemica
BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry. The full press release is below. Bioresource Technology joins Medix Biochemica Group Medix Biochemica broadens its capabilities in diagnostic base matrices […]
BroadOak Announces Investment in LabVoice
BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create proven efficiencies for customers. Newly commercial, the company has already […]
Biosynth Carbosynth Acquires Aalto Bio Reagents
BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 – Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to […]
BroadOak Q1 2022 M&A Newsletter
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 1Q 2022 BroadOak M&A Newsletter.
Biolog Announces New Leadership Team and Investment
BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification and phenotypic profiling technologies. Operating Partner Robert Wicke will serve as CEO of Biolog. Bill Snider and Robert Wicke will also serve on the company’s Board of Directors. The full press release is below. Biolog Announces New Leadership Team […]
Reaction Biology Acquired by Cobepa
BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction’s capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies, and an extensive array of cell-based assays. Reaction maintains one […]
Genomenon Raises $20M Series B Financing
BroadOak increased its investment in Genomenon, a company that organizes the world’s genomic data. The full press release is below. Genomenon Raises $20M Series B Financing, Launching a New Era in AI-Powered Genomic Data Financing led by Beringea and Spring Mountain Capital to fuel continued growth in pharmaceutical and clinical diagnostic markets Genomenon®Inc., an AI-driven […]
BroadOak Q4 2021 M&A Newsletter
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter.
Rockland Acquires Antibodies-Online
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: “We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland is a highly respected and innovative business that has […]